About Porton Pharmaceutical Technology
Porton Pharmaceutical Technology is a company based in Chongqing (China) founded in 2005. Porton Pharmaceutical Technology has raised $10 million across 1 funding round from investors including Detong Capital. The company has 5,450 employees as of December 31, 2024. Porton Pharmaceutical Technology has completed 1 acquisition, including J-Star Research. Porton Pharmaceutical Technology offers products and services including Small Molecules CDMO Services, Tides CDMO Services, Biologics and Conjugates CDMO Services, and Advanced Therapy Medicinal Products. Porton Pharmaceutical Technology operates in a competitive market with competitors including Laurus Labs, Sterling Pharma Solutions, Provepharm Life Solutions, Symbiotec and Jubilant Pharma, among others.
- Headquarter Chongqing, China
- Employees 5450 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Porton Pharma Solutions Ltd. Class A
-
Annual Revenue
$409.62 M (USD)-17.5as on Dec 31, 2024
-
Net Profit
-$39.42 M (USD)-207.83as on Dec 31, 2024
-
EBITDA
$23.66 M (USD)-73.94as on Dec 31, 2024
-
Total Equity Funding
$10 M (USD)
in 1 rounds
-
Latest Funding Round
$10 M (USD), Private Equity Round
Mar 03, 2010
- Investors
-
Employee Count
5450
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Porton Pharmaceutical Technology
Porton Pharmaceutical Technology is a publicly listed company on the SZSE with ticker symbol 300363 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Porton Pharmaceutical Technology
Porton Pharmaceutical Technology offers a comprehensive portfolio of products and services, including Small Molecules CDMO Services, Tides CDMO Services, Biologics and Conjugates CDMO Services, and Advanced Therapy Medicinal Products.
Custom development and production of small molecule APIs for partners.
Integrated CMC solutions for peptides and oligonucleotides development.
One-stop services for biologics including ADCs and conjugates.
End-to-end CRO and CDMO for viral vectors and mRNA therapies.
Funding Insights of Porton Pharmaceutical Technology
Porton Pharmaceutical Technology has successfully raised a total of $10M through 1 strategic funding round. The most recent funding activity was a Private Equity Round of $10 million completed in March 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Porton Pharmaceutical Technology
Porton Pharmaceutical Technology has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Detong Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked |
Investor details for Porton Pharmaceutical Technology
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Porton Pharmaceutical Technology
Porton Pharmaceutical Technology has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include J-Star Research.
Investment portfolio details for Porton Pharmaceutical Technology
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Custom synthesis and crystallization services for API development are provided.
|
Locked | Locked | 1996 | Locked |
Complete acquisition details for Porton Pharmaceutical Technology
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Porton Pharmaceutical Technology
Detailed financials for Porton Pharmaceutical Technology
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Porton Pharmaceutical Technology Comparisons
Peer comparison for Porton Pharmaceutical Technology
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Porton Pharmaceutical Technology
Porton Pharmaceutical Technology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Laurus Labs, Sterling Pharma Solutions, Provepharm Life Solutions, Symbiotec and Jubilant Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical and biotechnology company
|
|
| Locked | Locked | Locked |
Contract development, manufacturing, and analytical services for APIs are offered.
|
|
| Locked | Locked | Locked |
APIs and drug products are developed and valorized in pharmaceuticals.
|
|
| Locked | Locked | Locked |
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
|
|
| Locked | Locked | Locked |
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company.
|
|
| Locked | Locked | Locked |
APIs are manufactured and custom synthesis services are provided.
|
Detailed competitors of Porton Pharmaceutical Technology
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Porton Pharmaceutical Technology
Complete news archive for Porton Pharmaceutical Technology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Porton Pharmaceutical Technology
Porton Pharmaceutical Technology was founded in 2005 and raised its 1st funding round 5 years after it was founded.
Porton Pharmaceutical Technology is headquartered in Chongqing, China.
Nianfeng Ju is the current CEO of Porton Pharmaceutical Technology.
Porton Pharmaceutical Technology is a funded company, having raised a total of $10M across 1 funding round to date.
As of Dec 31, 2024, the latest employee count at Porton Pharmaceutical Technology is 5,450.
Annual revenue of Porton Pharmaceutical Technology is $409.62M as on Dec 31, 2024.
Porton Pharmaceutical Technology was founded in 2005 in Chongqing, China, where contract chemical development and manufacturing services are provided to the pharmaceutical industry. Research and development efforts focus on azides, chiral intermediates, synthons, building blocks, unnatural amino acids, heterocyclic compounds, and Grignard reagents. Manufacturing facilities have been approved by the USFDA, supporting operations in custom synthesis for global clients. Leadership is held by CEO Nianfeng Ju.
Porton Pharmaceutical Technology's top competitors include Laurus Labs, Symbiotec and Sterling Pharma Solutions.
Porton Pharmaceutical Technology offers Small Molecules CDMO Services, Tides CDMO Services, Biologics and Conjugates CDMO Services, and Advanced Therapy Medicinal Products.
Yes, Porton Pharmaceutical Technology is publicly traded on SZSE under the ticker symbol 300363.
Porton Pharmaceutical Technology has made 1 acquisition, including J-Star Research.
Porton Pharmaceutical Technology has 1 investor. Key investors include Detong Capital.
The ticker symbol of Porton Pharmaceutical Technology is 300363 on SZSE.